If you're seeing this message, that means
JavaScript has been disabled on your browser
, please
enable JS
to make this app work.
No tags found
Companies
No companies found
Advanced Search
Newsfeed
Alerts
Saved Lists
Sign Up for Free
Login
Update this Profile
Get Updates
5
Followers on Owler
Neurim is engaged in the development of drug therapies for the treatment of age-related disorders...
Read more
Overview
Competitors
News & Insights
Neurim is engaged in the development of drug therapies for the treatment of age-related disorders...
Read more
Co-Founder & CEO
Nava Zisapel
CEO Approval Rating
90/100
Weigh In
1991
Tel Aviv
Tel Aviv District
Private
Pharmaceuticals & Biotechnology
Biotechnology
Pharmaceuticals
2836
8731
NAICS listing
http://neurim.com/
Est. Annual Revenue
$5.0-25M
Agree?
Yes
No
Est. Employees
25-100
Agree?
Yes
No
News
Latest News
Jul 31, 2024
Pharmabiz
Neurim Pharmaceuticals: EMA committee recommends approval of Neurim Pharma's Slenyto to treat insomnia in children with NGDs
Aug 28, 2018
BioPortfolio
Neurim Pharmaceuticals: Neurim Pharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 11072018 Prices from USD $250
Jul 30, 2018
PharmiWeb
Neurim Pharmaceuticals: Neurim Pharmaceuticals Receives Positive CHMP Opinion for Slenyto (Pediatric Prolonged-Release Melatonin) for the Treatment of Insomnia in Children With Autism Spectrum Disorder (ASD)
Apr 29, 2018
BioPortfolio
Neurim Pharmaceuticals: Neurim Pharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13032018 Prices from USD $250
Jan 17, 2018
PR Newswire
Press Release: Neurim Pharmaceuticals : Neurim Pharmaceuticals' New Paediatric Prolonged-Release Melatonin ("PedPRM") to Be Marketed by BIOCODEX Oy in Finland
Oct 10, 2017
BioSpace
Neurim Pharmaceuticals: Positive Phase III Results For Neurim Pharmaceuticals' Pediatric Prolonged-Release Melatonin For Insomnia In Children With Autism Spectrum Disorder (ASD) Presented At In Prague
Sep 25, 2017
PR Newswire
Press Release: Neurim Pharmaceuticals : Neurim Pharmaceuticals' New Paediatric Prolonged-Release Melatonin ('PedPRM') to be Marketed by Flynn Pharma in UK and Ireland
Aug 30, 2017
BioPortfolio
Neurim Pharmaceuticals: Neurim Pharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 24082017 Prices from USD $250
Mar 28, 2017
BioSpace
Neurim Pharmaceuticals: Neurim Pharmaceuticals Grants Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") In Spain
Mar 12, 2017
BioSpace
Neurim Pharmaceuticals: Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin ('PedPRM') To Be Marketed By Biocodex In France
Follow and Get Alerts
Neurim Pharmaceuticals Competitors
1
Follow
2
Follow
3
Follow
4
Follow
5
Follow
6
Follow
7
Follow
8
Follow
9
Follow
10
Follow
Unlock 20 + competitors
Trending Companies